Epstein-BARR virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome

Pediatric Hematology and Oncology

Volumn 15, Issue 4, 1998, Pages 347-352

  Sasahara, Yoji ^a   Kawai, Shin ^a   Itano, Masayuki ^a   Kumaki, Satoru ^a   Fujie, Hiromi ^a   Minegishi, Masayoshi ^a   Tsuchiya, Shigeru ^a   Konno, Tasuke ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Donor leukocyte transfusion; Epstein Barr virus associated lymphoproliferative disorder; Unrelated bone marrow transplantation; Wiskott Aldrich syndrome

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOMODULATING AGENT; METHOTREXATE;

ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; LEUKOCYTE TRANSFUSION; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; WISKOTT ALDRICH SYNDROME;

EID: 0031836142     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019809014019     Document Type: Article

References (12)

1. Gratama JW. Epstein-Barr virus infection in bone marrow transplantation recipients. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific; 1994:429-442.
2. Oettle H, Wilborn F, Schmidt CA, Siegert W. Treatment with gancyclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation. Blood. 1993;82:2257-2258. Letter.
3. Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996;87:2594-2603.
4. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185-1192.
5. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-556.
6. Derry JMJ, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78:635-644.
7. Featherstone C. The many faces of WAS protein. Science. 1997;275:27-28.
8. Ozsahin H, Deist FL, Benkerrou M, et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr. 1996;129:238-244.
9. Lenarsky C, Weinberg K, Kohn DB, et al. Unrelated donor BMT for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 1993;12:145-147.
10. Imashuku S, Iwami H, Tsunamoto K, et al. Duration of Epstein-Barr virus (EBV)-associated polyclonal lymphoproliferative disease (LPD) following bone marrow transplantation. Bone Marrow Transplant. 1996;18:823-825. Letter.
11. Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995;89:98-103.
12. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.